

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A07/2017 WB

DESPATCHED ON 18TH JULY 2017

HLA PHENOTYPE OF BLOOD DONOR: A2, A3; B35, B65; Cw8, Cw-; DR4, DR13; DQ6, DQ7

					Summary of Results												
					PBL				T-Cells				B-Cells				
					8	8	8	8	20	18	20	20	14	18	17	17	
					2	2	0	0	0	0	0	0	1	18	0	0	
					6	6	8	8	20	18	20	20	13	0	17	17	
					2	2	2	2	0	2	0	0	7	3	4	4	
					25.0%	25.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	7.1%	100.0%	0.0%	0.0%	
					75.0%	75.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	92.9%	0.0%	100.0%	100.0%	
Consensus					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
HLA Antibody Specificity (Defined By CDC)					A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	
					Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments	
9	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Equivocal	Positive	Negative	Negative	PBL not tested due to low cell numbers Poor B-cell viability No B cell crossmatching performed due to issues with Dynabead supply B cell condition poor, high assay background for all samples. B-cell results not reported due to Dynabead recall The B-cells could not be properly tested due to contaminated Dynabeads. Serum 3 was clearly positive Serum 2 - further testing required to confirm a positive or negative result. Poor viability. In a clinical setting we would repeat the test Poor cell viability	
11	YES	YES	YES	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Equivocal	Positive	Negative	Negative		
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	Positive	NT	Negative		
20	YES		YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT		
23		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
24		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
25		YES	YES					Negative	Equivocal	Negative	Negative	NT	NT	NT	NT		
28		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
34		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
35	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative						
38	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
39		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
41		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
42	YES		YES	Negative	Negative	Negative	Negative					Positive	Positive	Negative	Equivocal		
45		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
51		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
54		YES	YES					Negative	Negative	Negative	Negative	Equivocal	Positive	Negative	Negative		
58		YES	YES					Negative	Equivocal	Negative	Negative	Negative	Positive	Negative	Negative		
117	YES			Positive	Negative	Negative	Negative										
136		YES						Negative	Negative	Negative	Negative						
149	YES			Positive	Negative	Negative	Negative										
205	YES		YES	NT	NT	NT	NT					NT	NT	NT	NT		
212		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
311		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		
315		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative		

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A07/2017 WB

DESPATCHED ON 18TH JULY 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	-	4	-	-	-	-	-	-	Equivocal	6	-	-	95	95	95
11	NT	NT	NT	NT	1	1	1	1	Equivocal	8	1	1		90	80
12	1	1	1	1	1	1	1	1	NT	8	NT	2	98	98	75
20	0	0	0	0					NT	NT	NT	NT	90		
23					1	1	1	1	1	8	1	1		95	60
24					10	10	10	10	30	100	30	30		90	70
25					1	Equivocal	1	1	NT	NT	NT	NT		90	
28					1	1	1	1	1	8	1	1		95	95
34					1	1	1	1	1	8	1	1		99	
35	2	2	2	2	2	2	2	2					90	90	
38	1	2	1	1	1	1	1	1	1	8	1	1	90	90	95
39					-	-	-	-	-	8	-	-		90	90
41					0	8	0	0	1	70	0	0	90	90	90
42	<10	<10	<10	<10					20-40	>80	<10	Equivocal	90		95
45					1	1	1	1	1	6	1	1		99	90
51					0	0	0	0	0	8	0	0		95	95
54					0-10	11-20	0-10	0-10	31-40	?90	11-20	0-10		95	90
58					<5	5-10	<5	<5	<15	99	<15	<15		95	85
117	2	1	1	1									75		
136					1	1	1	1						95	
149	2-4	-	-	-									80		
205	NT	NT	NT	NT					NT	NT	NT	NT			
212					-	-	-	-	-	-	-	-		100	100
311					1	1	1	1	1	8	1	1		95	95
315					1	1	1	1	1	6	1	1		75	75

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A07/2017 WB

DESPATCHED ON 18TH JULY 2017

HLA PHENOTYPE OF BLOOD DONOR: A2, A3; B35, B65; Cw8, Cw-; DR4, DR13; DQ6, DQ7

				Summary of Results												
				PBL				T-Cells				B-Cells				
				7	7	7	7	18	17	18	18	13	16	15	16	
Total tested				7	7	7	7	18	17	18	18	13	16	15	16	
Positive				1	2	0	0	0	1	0	0	0	16	0	0	
Negative				6	5	7	7	18	16	18	18	13	0	15	16	
NT/Equivocal				2	2	2	2	0	1	0	0	7	4	5	4	
% Positive				14.3%	28.6%	0.0%	0.0%	0.0%	5.9%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	
% Negative				85.7%	71.4%	100.0%	100.0%	100.0%	94.1%	100.0%	100.0%	100.0%	0.0%	100.0%	100.0%	
Consensus				Negative	Not Assessed	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
HLA Antibody Specificity (Defined By CDC)				A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Equivocal	Positive	Negative	Negative	PBL not tested due to low cell numbers
11	YES	YES	YES	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Equivocal	Positive	Negative	Negative	
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	Positive	NT	Negative	Poor B-cell viability
15		YES	YES						Positive			Negative	Positive	Negative	Negative	
20	YES		YES	Negative	Negative	Negative	Negative		NT			NT	NT	NT	NT	No B cell crossmatching performed due to issues with Dynabead supply
24		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	B-cell results not reported due to Dynabead recall
25		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	
28		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
34		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
35	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative					
38	YES	YES	YES	Negative	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
39		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
41		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
42	YES		YES	Negative	Negative	Negative	Negative					Negative	Positive	Negative	Negative	
45		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	The B-cells could not be properly tested due to contaminated Dynabeads. Serum 3 was clearly positive
51		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	No results reported due to known issue with class II Dynabeads
58		YES	YES					Negative	Equivocal	Negative	Negative	NT	NT	NT	NT	
149	YES			Positive	Negative	Negative	Negative									Poor cell viability
205	YES			NT	NT	NT	NT					NT	NT	NT	NT	
212		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
311		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
315		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A07/2017 WB

DESPATCHED ON 18TH JULY 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	-	4	-	-	-	-	-	-	Equivocal	6	-	-	95	95	95
11	NT	NT	NT	NT	1	1	1	1	Equivocal	8	1	1		90	80
12	1	1	1	1	1	1	1	1	NT	8	NT	2	98	98	75
15					0	2	0	0	0	8	0	0		90	90
20	0	0	0	0					NT	NT	NT	NT	90		
24					20	20	20	20	30	100	30	30		90	70
25					1	1	1	1	NT	NT	NT	NT		90	
28					1	1	1	1	1	8	1	1		95	95
34					1	1	1	1	1	8	1	1		99	
35	2	2	2	2	2	2	2	2					90	90	
38	1	2	1	1	1	1	1	1	1	8	1	1	90	90	95
39					-	-	-	-	-	8	-	-		90	90
41					3	11	4	1	0	81	0	3	90	90	90
42	<10	<10	<10	<10					<10	>80	<10	<10	90		95
45					1	1	1	1	1	6	1	1		99	90
51					0	0	0	0	0	8	0	0		95	95
58					<5	5-10	<5	<5	NT	NT	NT	NT		95	85
149	2-4	-	-	-									80		
205	NT	NT	NT	NT					NT	NT	NT	NT			
212					-	-	-	-	-	-	-	-		100	100
311					1	1	1	1	1	8	1	1		95	95
315					1	1	1	1	1	6	1	1		75	75